Dimensions of temperament and character as predictors of antidepressant discontinuation, response and adverse reactions during treatment with nortriptyline and escitalopram

被引:4
|
作者
Koehler-Forsberg, Ole [1 ,2 ]
Keers, Robert [3 ,4 ]
Uher, Rudolf [4 ,5 ]
Hauser, Joanna [6 ]
Maier, Wolfgang [7 ]
Rietschel, Marcella [8 ]
McGuffin, Peter [4 ]
Farmer, Anne E. [4 ]
Aitchison, Katherine J. [9 ,10 ]
Mors, Ole [1 ,2 ]
机构
[1] Aarhus Univ Hosp Psychiat, Psychosis Res Unit, Aarhus, Denmark
[2] Aarhus Univ, Dept Clin Med, Aarhus, Denmark
[3] Queen Mary Univ London, Dept Biol & Expt Psychol, London, England
[4] Kings Coll London, Social Genet & Dev Psychiat Ctr, Inst Psychiat Psychol & Neurosci, London, England
[5] Dalhousie Univ, Dept Psychiat, Halifax, NS, Canada
[6] Poznan Univ Med Sci, Dept Psychiat, Lab Psychiat Genet, Poznan, Poland
[7] Univ Bonn, Dept Psychiat, Bonn, Germany
[8] Heidelberg Univ, Med Fac Mannheim, Cent Inst Mental Hlth, Dept Genet Epidemiol Psychiat, Mannheim, Germany
[9] Univ Alberta, Dept Psychiat, Dept Med Genet, Edmonton, AB, Canada
[10] Univ Alberta, Neurosci & Mental Hlth Inst, Edmonton, AB, Canada
关键词
Antidepressant; depression; discontinuation; major depressive disorder (MDD); personality; response; PERSONALITY-TRAITS; INVENTORY TCI; DEPRESSION; ASSOCIATION; DISORDER; RELAPSE; SCALES; MOOD;
D O I
10.1017/S003329172100444X
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background Personality traits may predict antidepressant discontinuation and response. However, previous studies were rather small, only explored a few personality traits and did not include adverse drug effects nor the interdependency between antidepressant discontinuation patterns and response. Methods GENDEP included 589 patients with unipolar moderate-severe depression treated with escitalopram or nortriptyline for 12 weeks. Seven personality dimensions were measured using the self-reported 240-item Temperament and Character Inventory-Revised (TCI-R). We applied Cox proportional models to study discontinuation patterns, logistic and linear regression to investigate response and remission after 8 and 12 weeks, and mixed-effects linear models regarding time-varying treatment response and adverse drug reactions. Results Low harm avoidance, low cooperativeness, high self-transcendence and high novelty seeking were associated with higher risks for antidepressant discontinuation, independent of depressed mood, adverse drug reactions, drug, sex and age. Regression analyses showed that higher novelty seeking and cooperativeness scores were associated with a greater likelihood of response and remission after 8 and 12 weeks, respectively, but we found no correlations with response in the mixed-effects models. Only high harm avoidance was associated with more self-reported adverse effects. Conclusions This study, representing the largest investigation between several personality traits and response to two different antidepressants, suggests that correlations between personality traits and antidepressant treatment response may be confounded by differential rates of discontinuation. Future trials on personality in the treatment of depression need to consider this interdependency and study whether interventions aiming at improving compliance for some personality types may improve response to antidepressants.
引用
收藏
页码:2522 / 2530
页数:9
相关论文
共 13 条
  • [1] Temperament and character inventory dimensions as a predictor of response to antidepressant treatment in major depression
    Sato, T
    Hirano, S
    Narita, T
    Kusunoki, K
    Kato, J
    Goto, M
    Sakado, K
    Uehara, T
    JOURNAL OF AFFECTIVE DISORDERS, 1999, 56 (2-3) : 153 - 161
  • [2] Temperament and character inventory and response to antidepressant treatment
    De Carlo, V.
    Balestri, M.
    Souery, D.
    Montgomery, S.
    Kasper, S.
    Zohar, J.
    Mendlewicz, J.
    Serretti, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 : S437 - S437
  • [3] Trajectories of Suicidal Ideation During 12 Weeks of Escitalopram or Nortriptyline Antidepressant Treatment Among 811 Patients With Major Depressive Disorder
    Madsen, Trine
    Buttenschon, Henriette N.
    Uher, Rudolf
    Behrendt-Moller, Ida
    Perroud, Nader
    Maier, Wolfgang
    Hauser, Joanna
    Dernovsek, Mojca Zvezdana
    Henigsberg, Neven
    Souery, Daniel
    Rietschel, Marcella
    McGuffin, Peter
    Aitchison, Katherine J.
    Mors, Ole
    Koehler-Forsberg, Ole
    JOURNAL OF CLINICAL PSYCHIATRY, 2019, 80 (04)
  • [4] Tissue-Specific Oxysterols as Predictors of Antidepressant (Escitalopram) Treatment Response in Patients With Major Depressive Disorder
    Sun, Zuoli
    Yang, Jian
    Zhou, Jia
    Zhou, Jingjing
    Feng, Lei
    Feng, Yuan
    He, Yi
    Liu, Min
    Li, Yuhong
    Wang, Gang
    Li, Rena
    BIOLOGICAL PSYCHIATRY: GLOBAL OPEN SCIENCE, 2023, 3 (04): : 663 - 672
  • [5] Concomitant antidepressant treatment during acute electroconvulsive therapy (ECT): Enhanced response, low risk of adverse effects
    Isenberg, K.
    Haskett, R.
    McCail, V.
    Mulsant, B.
    Prudic, J.
    Hussain, M.
    Pierce, K.
    Sackeim, H.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S192 - S193
  • [6] Concomitant antidepressant treatment during acute electroconvulsive therapy (ECT): Enhanced response, low risk of adverse effects
    Isenberg, K.
    Haskett, R.
    McCall, V.
    Mulsant, B.
    Prudic, J.
    Hussain, M.
    Pierce, K.
    Sackeim, H.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S137 - S137
  • [7] Cardiovascular Adverse Reactions During Antidepressant Treatment: A Drug Surveillance Report of German-Speaking Countries Between 1993 and 2010
    Spindelegger, Christoph Josef
    Papageorgiou, Konstantinos
    Grohmann, Renate
    Engel, Rolf
    Greil, Waldemar
    Konstantinidis, Anastasios
    Agelink, Marcus Willy
    Bleich, Stefan
    Ruether, Eckart
    Toto, Sermin
    Kasper, Siegfried
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2015, 18 (04): : 1 - 9
  • [8] Prevalence and predictors of patients reporting adverse drug reactions to health care providers during oral targeted cancer treatment
    Monestime, Shanada
    Page, Ray
    Jordan, William M.
    Aryal, Subhash
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2021, 61 (01) : 53 - 59
  • [9] Biliary adverse events in acromegaly during somatostatin receptor ligands: predictors of onset and response to ursodeoxycholic acid treatment
    Prencipe, N.
    Bona, C.
    Cuboni, D.
    Parasiliti-Caprino, M.
    Berton, A. M.
    Fenoglio, L. M.
    Gasco, V.
    Ghigo, E.
    Grottoli, S.
    PITUITARY, 2021, 24 (02) : 242 - 251
  • [10] Biliary adverse events in acromegaly during somatostatin receptor ligands: predictors of onset and response to ursodeoxycholic acid treatment
    N. Prencipe
    C. Bona
    D. Cuboni
    M. Parasiliti-Caprino
    A. M. Berton
    L. M. Fenoglio
    V. Gasco
    E. Ghigo
    S. Grottoli
    Pituitary, 2021, 24 : 242 - 251